17 jul: Parken: FCK forhandler med flere om N'Doye-salg
18 jul: OPTAKT Nordea Q2 18/7: Drift holdt nede af nedskrivninger
17-07-2012 23:37:00

GlaxoSmithKline and Amicus Expand Drug Collaboration

Relateret indhold

By Ben Fox Rubin

Amicus Therapeutics Inc. (FOLD) and GlaxoSmithKline PLC (GSK, GSK.LN) said they are expanding their collaboration to develop a treatment for Fabry disease, with Glaxo agreeing to buy a larger stake in the smaller pharmaceutical company.

The deal includes co-development of all current and future formulations of migalastat HCl for Fabry disease, which is a lipid storage disorder, as well as a commercialization arrangement for all future Fabry products. Amicus will have commercial rights in the U.S., while Glaxo will have rights for the rest of the world.

Glaxo also agreed to buy $18.6 million in Amicus's common stock at $6.30 a share, a 4.7% premium over Tuesday's close, raising its ownership in the company to 20%.

"Through our expanded agreement, GSK is increasing its investment in the Fabry development program and Amicus is transforming into a commercial-stage biopharmaceutical company within the U.S.," said Amicus Chief Executive John Crowley.

Amicus makes oral therapeutics known as pharmacological chaperones to treat a range of human genetic diseases.

Its shares closed Tuesday at $6.02, while Glaxo's closed at $45.44. Neither were active after hours.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 17, 2012 17:37 ET (21:37 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/middag: C20 går lidt tilbage efter morgenens fremgang

30-07-2015 11:40:07
Novo Nordisk fører an i C20 på en dag, der er præget af en stime af regnskaber fra det europæiske kontinent.C20 Cap-indekset torsdag middag er relativt ligeligt..

Novo: Sanofi leverer fremgang trods fald i diabetes-salg

30-07-2015 07:49:37
Det franske medicinalselskab Sanofi kom bedre end ventet ud af selskabets andet kvartal, men franskmændene kunne alligevel ikke forhindre endnu en tilbagegang i..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Gamesa falder voldsomt på børsen efter regnskabet
2
Vestas/Nykredit: Positive signaler i konkurrentregnskaber
3
Torsdagens aktier: Vestas bundprop i rødt C20
4
Aktier/middag: C20 går lidt tilbage efter morgenens fremgang
5
Aktier/tendens: Positiv start i sigte med udenlandsk præg

Relaterede aktiekurser

GlaxoSmithKline PLC 1.371,02 -0,3% Fald i aktiekurs
GlaxoSmithKline PLC 43,61 2,3% Stigning i aktiekurs
Amicus Therapeutics Inc 16,40 -1,0% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. juli 2015 22:16:18
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150716.1 - EUROWEB1 - 2015-07-30 22:16:18 - 2015-07-30 22:16:18 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x